Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06629584 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
A Phase 2 study of Malignant Solid Tumors, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06629584: Recruiting Phase 2 study of Malignant Solid Tumors, sponsored by M.D. Anderson Cancer Center.
NCT06629584 is a Phase 2 study of Malignant Solid Tumors that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 3,381-participant average among 3 other Malignant Solid Tumors trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06629584, a Phase 2 study of Malignant Solid Tumors, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label, phase 2 study investigating asciminib in patients previously treated with one line of TKI therapy.
Primary Outcome
MMR rate at 12 months with the 95% confidence interval will also be estimated.
Conditions Studied
Interventions
- DRUG Asciminib
Study Locations (1)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-02-14 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
What NCT06629584 shows while recruiting
NCT06629584 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 3,381-participant average among 3 other Malignant Solid Tumors trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Malignant Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Asciminib is the first listed.
NCT06629584 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06629584 about?
NCT06629584 is a clinical study titled "Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia". This is an open label, phase 2 study investigating asciminib in patients previously treated with one line of TKI therapy.
What is the current status of trial NCT06629584?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-02-14. Estimated completion is 2028-12-31.
What conditions does trial NCT06629584 study?
This clinical trial studies the following conditions: Malignant Solid Tumors.
What interventions are being tested in trial NCT06629584?
The interventions under investigation include: Asciminib (DRUG).
Who is sponsoring clinical trial NCT06629584?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06629584 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI